An increasing number of studies has verified that the RAF/MEK/ERK and PI3K/PDK1/Akt signaling axes are hyperactivated in various tumors, making them potential targets for new anti-cancer agents (Hrustanovic et al., 2015; McCarroll et al., 2015). This evidence concerns the gene MAP2K7 and cancer.